139 related articles for article (PubMed ID: 11354305)
1. Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients.
Griffiths RI; Bar-Din M; MacLean C; Sullivan EM; Herbert RJ; Yelin EH
Ther Apher; 2001 Apr; 5(2):92-104. PubMed ID: 11354305
[TBL] [Abstract][Full Text] [Related]
2. Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy.
Griffiths RI; Bar-Din M; MacLean CH; Sullivan EM; Herbert RJ; Yelin EH
Arthritis Care Res; 2000 Aug; 13(4):213-26. PubMed ID: 14635276
[TBL] [Abstract][Full Text] [Related]
3. Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis.
Boytsov NN; Bhattacharya R; Saverno K; Dixon L; Abbott PL; Zhang X; Gaich CL; Nair R
J Manag Care Spec Pharm; 2019 Aug; 25(8):879-887. PubMed ID: 31347977
[TBL] [Abstract][Full Text] [Related]
4. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
5. Geographic Variation in the Quality and Cost of Care for Patients with Rheumatoid Arthritis.
Shafrin J; Ganguli A; Gonzalez YS; Shim JJ; Seabury SA
J Manag Care Spec Pharm; 2016 Dec; 22(12):1472-1481. PubMed ID: 27882832
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study.
Bonafede MM; Fox KM; Johnson BH; Watson C; Gandra SR
Clin Ther; 2012 Feb; 34(2):457-67. PubMed ID: 22284901
[TBL] [Abstract][Full Text] [Related]
7. Economic Evaluation of Anticyclic Citrullinated Peptide Positivity in Rheumatoid Arthritis.
An J; Bider-Canfield Z; Kang J; Alemao E; Connolly SE; Lin AT; Cheetham TC
J Manag Care Spec Pharm; 2019 Apr; 25(4):469-477. PubMed ID: 30917075
[TBL] [Abstract][Full Text] [Related]
8. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Rheumatoid Arthritis and Drug Dispensing Patterns Among Medicaid and Medicaid-Medicare Dually Eligible Beneficiaries in Puerto Rico.
Hernández-Muñoz JJ; Wei W; Sierra-Zorita R
Arthritis Care Res (Hoboken); 2021 Feb; 73(2):199-206. PubMed ID: 32475025
[TBL] [Abstract][Full Text] [Related]
10. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
[TBL] [Abstract][Full Text] [Related]
11. Impact of Out-of-Pocket Costs on Prescription Fills Among New Initiators of Biologic Therapies for Rheumatoid Arthritis.
Hopson S; Saverno K; Liu LZ; AL-Sabbagh A; Orazem J; Costantino ME; Pasquale MK
J Manag Care Spec Pharm; 2016 Feb; 22(2):122-30. PubMed ID: 27015251
[TBL] [Abstract][Full Text] [Related]
12. Disease-modifying antirheumatic drug initiation among patients newly diagnosed with rheumatoid arthritis.
Bonafede M; Johnson BH; Shah N; Harrison DJ; Tang D; Stolshek BS
Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP279-SP285. PubMed ID: 30020740
[TBL] [Abstract][Full Text] [Related]
13. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
Sokka T; Pincus T
J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis.
Osiri M; Kamolratanakul P; Maetzel A; Tugwell P
Rheumatol Int; 2007 Sep; 27(11):1063-9. PubMed ID: 17440729
[TBL] [Abstract][Full Text] [Related]
15. Changes in use of disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States during 1983-2009.
Kim SC; Yelin E; Tonner C; Solomon DH
Arthritis Care Res (Hoboken); 2013 Sep; 65(9):1529-33. PubMed ID: 23463543
[TBL] [Abstract][Full Text] [Related]
16. The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database.
Edwards CJ; Arden NK; Fisher D; Saperia JC; Reading I; Van Staa TP; Cooper C
Rheumatology (Oxford); 2005 Nov; 44(11):1394-8. PubMed ID: 16030083
[TBL] [Abstract][Full Text] [Related]
17. Brief Report: Intensification to Triple Therapy After Treatment With Nonbiologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States From 2009 to 2014.
Sparks JA; Krumme AA; Shrank WH; Matlin OS; Brill G; Pezalla EJ; Choudhry NK; Solomon DH
Arthritis Rheumatol; 2016 Jul; 68(7):1588-95. PubMed ID: 26866506
[TBL] [Abstract][Full Text] [Related]
18. Determinants of first-line biological treatment in patients with rheumatoid arthritis: Results from an observational study.
Angelici L; Addis A; Agabiti N; Kirchmayer U; Davoli M; Belleudi V
Medicine (Baltimore); 2021 May; 100(19):e25943. PubMed ID: 34106665
[TBL] [Abstract][Full Text] [Related]
19. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
[TBL] [Abstract][Full Text] [Related]
20. [Disease-modifying treatment for inflammatory rheumatism in sub-Saharan Africa: outcome at 6 months of 205 Senegalese patients with rheumatoid arthritis].
Ndongo S; Pouye A; Lekpa FK; Bihéhé DM; Tiendrebeogo J; Ndao AC; Ka MM; Moreira Diop T
Med Sante Trop; 2012; 22(4):385-9. PubMed ID: 23352953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]